Policy Developments - The 2025 Pharmaceutical Digital Development Conference was held in Beijing on September 17-18, focusing on the modernization of drug regulation through information technology and digital collaboration [1] Drug and Device Approvals - Hengrui Medicine's SHR-1501 has been included in the list of proposed breakthrough therapy varieties by the National Medical Products Administration, aimed at treating non-muscle invasive bladder cancer [2] - Kehua Bio's ferritin assay kit received a medical device registration certificate, valid from September 17, 2025, to September 16, 2030, for the quantitative measurement of ferritin in human serum and plasma [3] - Shanghai Pharmaceuticals' Nicorandil tablets passed the consistency evaluation for generic drugs, with approximately 5.5352 million yuan invested in R&D [4] Capital Market - Roche announced a definitive agreement to acquire biopharmaceutical company 89bio for up to nearly $3.5 billion, focusing on innovative therapies for liver and heart metabolic diseases [5] Industry Events - The first national group standard for "Non-Clinical Safety Technical Guidelines for Oligonucleotide Drugs" was released during the 9th China (Tianjin) Nucleic Acid Drug Conference [6] Research and Development - Chinese researchers developed a new generation of brain-machine interface electrodes, marking a shift towards dynamic and intelligent detection in bioelectronic interfaces [7] - A new blood testing tool, "HPV-DeepSeek," can identify HPV-related head and neck cancers up to 10 years before symptoms appear, potentially improving patient outcomes [9] Corporate Governance - The independent director of Buchang Pharma, Cheng Hua, resigned due to personal reasons, leading to a temporary reduction in the number of independent directors on the board [10] Strategic Collaborations - Siemens Healthineers and Stryker announced a strategic partnership to develop a new robotic system for neurovascular interventions [8]

Market Performance - The S&P 500 Index closed up +0.48%, the Dow Jones Industrials Index up +0.27%, and the Nasdaq 100 Index up +0.95% on Thursday, with all three indexes reaching new record highs [1][2] - September E-mini S&P futures rose +0.50%, and September E-mini Nasdaq futures rose +0.92% [1] Economic Indicators - Weekly initial unemployment claims fell by -33,000 to 231,000, indicating a stronger labor market than the expected 240,000 [5] - The September Philadelphia Fed business outlook survey rose by +23.5 to an 8-month high of 23.2, surpassing expectations of 1.7 [5] - August leading indicators fell -0.5% month-over-month, which was weaker than the expected -0.2% and marked the largest decline in four months [6] Sector Performance - Semiconductor stocks led the technology sector higher, with Intel surging more than +22% after Nvidia announced a $5 billion investment in the company for co-developing chips [2][12] - Other notable gainers in the semiconductor sector included KLA Corp, ASML Holding NV, and Applied Materials, all closing up more than +6% [12] Company News - CrowdStrike Home closed up more than +12% following an investor briefing discussing its AI strategy and a strong preliminary fiscal 2027 outlook [13] - 89bio closed up more than +85% after Roche announced its intention to acquire the company for $3.5 billion or $14.50 per share [13] - Allstate closed up more than +4% after reporting August catastrophe losses of $168 million, down -8.7% month-over-month [14] - Cooper Companies closed up more than +4% after its board approved a $1 billion increase in its stock buyback program [14] Earnings Reports - FactSet Research Systems closed down more than -10% after reporting Q4 adjusted EPS of $4.05, below the consensus of $4.15, and forecasting 2026 adjusted EPS weaker than expected [15] - Darden Restaurants closed down more than -7% after forecasting 2026 adjusted EPS below consensus [16]

Today in Bloomberg Deals: BayPine targets AI overhaul candidates, Nvidia invests in Intel and Roche agrees to buy 89bio https://t.co/pwBMlh4X2K ...

Acquisition Overview - Roche Holdings AG has agreed to acquire 89bio, Inc. for $2.4 billion, focusing on therapies for liver and cardiometabolic diseases [1] - The acquisition price is set at $14.50 per share, reflecting a 79% premium over 89bio's closing stock price on September 17, 2025, and a 52% premium over its 60-day volume-weighted average price [2] Contingent Value Rights (CVR) - 89bio stockholders will receive a non-tradeable CVR, allowing for contingent payments of up to $6.00 per share based on specific milestones, bringing the total transaction equity value to approximately $3.5 billion on a fully diluted basis [3] - The CVR includes payments of $2.00 per share upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients, $1.50 per share upon reaching annual net sales of $3.0 billion, and $2.50 per share upon reaching annual net sales of $4.0 billion [5] Product Development - 89bio's pegozafermin, an FGF21 analog, is in late-stage development for MASH in moderate to severe fibrotic patients and cirrhotic patients [4] - Roche aims to enhance its pipeline targeting metabolic diseases through this acquisition, with potential best-in-disease efficacy for moderate to severe MASH patients [5] Market Reaction - Following the announcement, 89bio's stock price increased by 85.15%, reaching $14.97 [6]

Group 1 - Two stocks in the health care sector are signaling potential warnings for momentum-focused investors as of September 18, 2025 [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] - Major overbought stocks in the health care sector include 89bio Inc and Anteris Technologies Global Corp [3] Group 2 - 89bio has agreed to be acquired by Roche for $14.50 per share, representing a 79% premium over its closing stock price on September 17, with an RSI value of 82.2 [6] - 89bio's stock has a 52-week high of $11.84 and gained 1.4% to close at $8.08 on Wednesday [6] - Anteris Technologies reported mixed quarterly results, with a stock gain of approximately 48% over the past month and a 52-week high of $8.79, but its shares fell 1.8% to close at $5.61 [6]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones. Halper Sadeh encourages 89bio sha. ...

Group 1 - Darden Restaurants Inc. (DRI) is expected to report quarterly earnings of $2.00 per share with revenue of $3.04 billion [2] - Bullish BLSH reported a profit of 93 cents per share for the second quarter, recovering from a loss of $1.03 per share a year ago, with revenue increasing to $58.63 million from $49.57 million [2] - Factset Research Systems Inc. (FDS) is anticipated to post quarterly earnings of $4.13 per share on revenue of $593.45 million [2] - 89bio Inc. (ETNB) has agreed to be acquired by Roche for $14.50 per share, representing a 79% premium to its closing stock price on September 17 [2] - FedEx Corp. (FDX) is expected to report quarterly earnings of $3.62 per share with revenue of $21.67 billion [2]

Core Viewpoint - The Ademi Firm is investigating 89bio for potential breaches of fiduciary duty and other legal violations related to its transaction with Roche [1] Group 1 - 89bio shareholders will receive $14.50 per share in cash at closing [1] - Shareholders will also receive a non-tradeable contingent value right (CVR) for certain milestone payments [1]

Roche Holding says it will acquire biopharmaceutical company 89bio in a deal valued at $3.5 billion, bolstering the Swiss pharmaceutical giant’s pipeline of cardiovascular, renal, and metabolic disease treatments https://t.co/9tmRggnAGn ...

The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity comorbidity. ...